Product Introduction
Bioactivity


英文名: Allitinib

描述: Allitinib (AST-1306) 是可口服的 EGFR 和 ErbB2不可逆抑制剂，IC50分别为 0.5 和 3 nM。它具有抗癌活性，抑制 ErbB4，IC50为 0.8 nM。

体外活性: AST1306 (AST-1306; 0.19-6.25 μM; 72 hours) inhibit the growth of HIH3T3-EGFR T790M/L858R cells[1]. AST1306 (0.001-1.0 μM; 4 hours) is more than 3000-fold selective for ErbB family kinases over other kinase families[1]. AST1306 inhibits the activation of tyrosine kinases and downstream signaling pathways in A549 cells, Calu-3 cells and SK-OV-3 cells，and dose-dependently and markedly inhibits EGF-induced EGFR phosphorylation in A549 cells[1].

体内活性: AST1306 (AST-1306; oral; 25-100 mg/kg) significantly inhibited tumor growth in SK-OV-3 and Calu-3 xenograft models[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 20 mg/mL (44.56 mM)


关键字: anilino-quinazoline | Inhibitor | anti-cancer | Epidermal growth factor receptor | ALS1306 | Irreversible | HER1 | inhibit | ErbB-1 | AST1306 | ALS-1306 | Allitinib | AST 1306 | EGFR

相关产品: Trastuzumab | Saracatinib | Poziotinib | EGFR-IN-85 | Chamigrenal | PD158780 | Cyasterone | EGFR-IN-83 | MTX-211 | Biochanin A

相关库: Drug Repurposing Compound Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Active Compound Library | Tyrosine Kinase Inhibitor Library | NO PAINS Compound Library